A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens

Virology Journal

Volumn 7, Issue , 2010, Pages

  Vizoso Pinto, Maria G ^a   Pfrepper, Klaus Ingmar ^b   Janke, Tobias ^b   Noelting, Christina ^b   Sander, Michaela ^b   Lueking, Angelika ^c   Haas, Juergen ^a,d   Nitschko, Hans ^a   Jaeger, Gundula ^a   Baiker, Armin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MIKROGEN GMBH   (Germany)

^c PROTAGEN AG   (Germany)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ANTIGEN; VIRUS ANTIBODY; VIRUS PROTEIN;

ANTIGEN DETECTION; ARTICLE; CHICKENPOX; ENZYME LINKED IMMUNOSORBENT ASSAY; HERPES ZOSTER; MICROARRAY ANALYSIS; NONHUMAN; OPEN READING FRAME; PROTEIN EXPRESSION; SERODIAGNOSIS; VARICELLA ZOSTER VIRUS; VIRUS IDENTIFICATION; VIRUS REACTIVATION; BLOOD; EVALUATION; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METHODOLOGY; SEROLOGY; VIROLOGY;

BACTERIA (MICROORGANISMS); HERPES ZOSTER; HUMAN HERPESVIRUS 3;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHICKENPOX; GENE EXPRESSION; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; IMMUNOGLOBULIN M; MICROARRAY ANALYSIS; OPEN READING FRAMES; SEROLOGIC TESTS; VIRAL PROTEINS;

EID: 77954671358     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-165     Document Type: Article

References (33)

1. Varicella vaccine - the first six years. AM Arvin, N Engl J Med 2001 344 1007 1009 10.1056/NEJM200103293441310 11274629
2. Loss of vaccine-induced immunity to varicella over time. SS Chaves P Gargiullo JX Zhang R Civen D Guris L Mascola JF Seward, N Engl J Med 2007 356 1121 1129 10.1056/NEJMoa064040 17360990
3. Vaccination to prevent varicella and shingles. J Breuer, J Clin Pathol 2001 54 743 747 11577118
4. Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine. B Watson, J Infect Dis 2008 197 Suppl 2 143 146 10.1086/522130 18419388
5. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics 2007 120 221 231 10.1542/peds.2007-1089 17606582
6. STIKO recommendation. Book STIKO recommendation City: Robert Koch Institute 2009 (Editor ed.eds.), vol. 30
7. Viral strain identification in varicella vaccinees with disseminated rashes. P LaRussa SP Steinberg E Shapiro M Vazquez AA Gershon, Pediatr Infect Dis J 2000 19 1037 1039 10.1097/00006454-200011000-00002 11099082
8. Preventing varicella-zoster disease. S Hambleton AA Gershon, Clin Microbiol Rev 2005 18 70 80 10.1128/CMR.18.1.70-80.2005 15653819
9. Varicella-zoster virus. AM Arvin, Clin Microbiol Rev 1996 9 361 381 8809466
10. New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. AJ Davison CM Edson RW Ellis B Forghani D Gilden C Grose PM Keller A Vafai Z Wroblewska K Yamanishi, J Virol 1986 57 1195 1197 3005621
11. Early detection of Varicella-Zoster Virus (VZV)-specific T-cells before seroconversion in primary varicella infection: case report. A Baiker R Haase J Eberle MG Vizoso Pinto KI Pfrepper A Petrich L Deml H Campe H Nitschko G Jaeger, Virol J 2010 7 54 10.1186/1743-422X-7-54 20205920
12. Purification of a recombinantly produced transmembrane protein (gp41) of HIV I. E Soutschek B Hoflacher M Motz, J Chromatogr 1990 521 267 277 10.1016/0021-9673(90)85051-V 2286639
13. Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. V Williams A Gershon PA Brunell, J Infect Dis 1974 130 669 672 4372275
14. Detection of antibodies to varicella-zoster virus using a latex agglutination assay. AA Gershon P Larussa S Steinberg, Clin Diagn Virol 1994 2 271 277 10.1016/0928-0197(94)90051-5 15566772
15. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Breuer DS Schmid AA Gershon, J Infect Dis 2008 197 Suppl 2 147 151 10.1086/529448 18419389
16. Comparison of latex agglutination test with enzyme-linked immunosorbent assay for detection of antibody to varicella-zoster virus. ML Landry D Ferguson, J Clin Microbiol 1993 31 3031 3033 8263191
17. A cluster of primary varicella cases among healthcare workers with false-positive varicella zoster virus titers. A Behrman DS Schmid A Crivaro B Watson, Infect Control Hosp Epidemiol 2003 24 202 206 10.1086/502187 12683513
18. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. EH Wasmuth WJ Miller, J Med Virol 1990 32 189 193 10.1002/jmv.1890320310 2177782
19. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults. DL Krah I Cho T Schofield RW Ellis, Vaccine 1997 15 61 64 10.1016/S0264-410X(96)00107-7 9041667
20. Serological detection of specific IgG to varicella-zoster virus by novel ELISA based on viral glycoprotein antigen. A Sauerbrei P Wutzler, Clin Lab 2009 55 1 7 19350844
21. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. A Sauerbrei P Wutzler, J Clin Microbiol 2006 44 3094 3097 10.1128/JCM.00719-06 16954232
22. Varicella-zoster virus ORF1 gene product is a tail-anchored membrane protein localized to plasma membrane and trans-Golgi network in infected cells. T Koshizuka T Sadaoka H Yoshii K Yamanishi Y Mori, Virology 2008 377 289 295 10.1016/j.virol.2008.04.039 18570967
23. Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency. JI Cohen T Krogmann JP Ross L Pesnicak EA Prikhod'ko, J Virol 2005 79 6969 6975 10.1128/JVI.79.11.6969-6975.2005 15890936
24. Deletion in open reading frame 49 of varicella-zoster virus reduces virus growth in human malignant melanoma cells but not in human embryonic fibroblasts. T Sadaoka H Yoshii T Imazawa K Yamanishi Y Mori, J Virol 2007 81 12654 12665 10.1128/JVI.01183-07 17855513
25. Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection. L Jones AP Black GN Malavige GS Ogg, J Virol 2006 80 9772 9778 10.1128/JVI.00564-06 16973581
26. Immunization with a DNA vaccine expressing a truncated form of varicella zoster virus glycoprotein E. UA Hasan DR Harper BW Wren WJ Morrow, Vaccine 2002 20 1308 1315 10.1016/S0264-410X(01)00475-3 11818149
27. Serological microarray for detection of HSV-1, HSV-2, VZV, and CMV antibodies. AJ Jaaskelainen K Moilanen S Buhler M Lappalainen O Vapalahti A Vaheri H Piiparinen, J Virol Methods 2009 160 167 171 10.1016/j.jviromet.2009. 05.013 19477202
28. Systematic analysis of the IgG antibody immune response against Varicella Zoster virus (VZV) using a self-assembled protein microarray (NAPPA). A Ceroni S Sibani A Baiker VR Pothineni SM Bailer J LaBaer J Haas C Campbell, Mol BioSyst 2010 DOI : 10.1039/c003798b 20514382
29. VZV infection in pregnancy: a retrospective review over 5 years in Sheffield and discussion on the potential utilisation of varicella vaccine in prevention. MW McKendrick J Lau S Alston J Bremner, J Infect 2007 55 64 67 10.1016/j.jinf.2007.02.003 17418420
30. Herpesviral protein networks and their interaction with the human proteome. P Uetz YA Dong C Zeretzke C Atzler A Baiker B Berger SV Rajagopala M Roupelieva D Rose E Fossum J Haas, Science 2006 311 239 242 10.1126/science. 1116804 16339411
31. Protein microarrays for gene expression and antibody screening. A Lueking M Horn H Eickhoff K Bussow H Lehrach G Walter, Anal Biochem 1999 270 103 111 10.1006/abio.1999.4063 10328771
32. Seroreactivity to and avidity for recombinant antigens in toxoplasmosis. KI Pfrepper G Enders M Gohl D Krczal H Hlobil D Wassenberg E Soutschek, Clin Diagn Lab Immunol 2005 12 977 982 16085916
33. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection. KI Pfrepper M Enders M Motz, J Vet Med B Infect Dis Vet Public Health 2005 52 362 365 16316402